Skip to main content

Advertisement

Table 3 Baseline minority resistance mutations detected by ultra-deep sequencing

From: Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?

ID Virological outcome after at least 6 months of HAART Genotype Baseline resistance mutations (% prevalence) Drug activity of initiated regimen (Based on drug resistance mutation surveillance list [31]) Drug activity of initiated regimen (Based on impact of treatment efficacy Stanford HIVdb algorithm)
NRTIs NNRTIs TAMS
L001 Suppressed C D67E (1.67) T69N (1.25) F77L (2.16) P225H (1.35) F227L (2.36) 1 TDF and FTC resistance EFV resistance TDF susceptible FTC susceptible EFV resistance
L009 Detectable viremia (<1000 RNA copies/ml) C D67E (1.29) T69N (1.03) F77L (1.15) L100I (1.15) KI03N (4.17) F227L (1.49) 1 TDF and FTC resistance EFV resistance TDF susceptible FTC susceptible EFV high level resistance
L013 Virological failure C D67E (1.73) T69N (1.21) F77L (1.13) P225H (1.16) F227L (1.98) 1 TDF and FTC resistance EFV resistance TDF susceptible FTC susceptible EFV low level resistance
L031 Virological failure C D67E (1.05) F77L (1.02) F227L (1.78) 1 TDF and FTC susceptible EFV resistance TDF susceptible FTC susceptible EFV resistance
L054 Virological failure C A62V (1.51) D67E (1.16) F77L (1.52) F227L (1.26) 1 TDF resistance and FTC susceptible EFV resistance TDF resistance FTC susceptible EFV resistance
L064 Virological failure C D67E (1.32) F227L (1.43) 1 TDF and FTC susceptible EFV susceptible TDF susceptible FTC susceptible EFV resistance
L074 Suppressed CRF37_cpx D67E (1.72) T69N (1.34) M184I (1.04) P225H (1.12) F227L (1.86) 1 TDF and FTC resistance EFV resistance TDF susceptible FTC resistance EFV resistance
L075 Suppressed CRF37_cpx D67E (1.83) T69N (1.58) L74V (1.23) F77L (1.01) M184I (1.44) P225H (2.22) F227L (1.47) 1 TDF and FTC resistance EFV resistance TDF susceptible FTC resistance EFV low level resistance